CBER/CDER Reorganization Will Lengthen Reviews, Ex-FDAer Warns HHS

FDA's proposed transfer of therapeutic biological product reviews to the Center for Drug Evaluation & Research could lead to longer review times due to decreased emphasis on staff research, a former Center for Biologics Evaluation & Research division director told HHS